Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Study: Capecitabine with concurrent radiation is effective for treating gastric cancer

Gastric cancer is a major cause of cancer deaths in the world. The outcome of large gastric tumors and those with lymph node involvement remains poor after surgical resection. The optimal adjuvant therapy after surgical resection remains to be determined.

21 Sep 2010

Abbott to commercialize Celera's CE-marked KIF6 genotyping assay outside U.S.

Celera Corporation and Abbott today announced that they have signed an exclusive distribution agreement to market Celera's CE-marked KIF6 diagnostic test for use on Abbott's CE-marked m2000™ instrument system. The KIF6 genotyping assay detects a genetic marker that may be used in conjunction with clinical evaluation and patient assessment for the identification of individuals at risk for coronary heart disease (CHD), and in patients for whom statin treatment is being considered.

20 Sep 2010

FDA decides to review information on Avastin for advanced HER2-negative breast cancer

Genentech, Inc., a member of the Roche Group, today announced that information submitted by the company to the U.S. Food and Drug Administration (FDA) during the review of the supplemental Biologics License Applications (sBLAs) for Avastin (bevacizumab) for previously untreated (first-line) advanced HER2-negative breast cancer has been deemed a major amendment.

18 Sep 2010

Researchers identify bacteria responsible for chronic intestinal inflammation

Certain bacteria that inhabit the intestine provide the environmental trigger that initiates and perpetuates chronic intestinal inflammation in individuals who are genetically susceptible to inflammatory bowel disease (IBD), a study led by Harvard School of Public Health researchers has found.

17 Sep 2010

PAF announces expansion of Colorectal Care Line

The Patient Advocate Foundation (PAF), a national non-profit resolving patient access to health care issues, medical financial limitations, insurance denials and multiple government program enrollments, including Medicaid and Social Security Disability Income announced today a significant expansion of its Colorectal Care Line (CCL), beginning September 13, 2010.

15 Sep 2010

Transgenomic expands EU distribution of SURVEYOR Scan K-RAS CE IVD mutation detection kit

Transgenomic, Inc. today announced that it completed the requirements for CE IVD labeling and has significantly expanded distribution of its SURVEYOR® Scan K-RAS mutation detection kit throughout most of the European Union. The SURVEYOR Scan K-RAS CE IVD kit is a member of Transgenomic's family of mutation detection kits, which features proprietary SURVEYOR endonuclease technology.

14 Sep 2010

Pro-Pharmaceuticals engages Numoda Corporation to optimize DAVANAT Phase III clinical trial

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that it has engaged the Numoda Corporation, a leading information, process and logistics management company, to oversee the Phase III clinical trial of DAVANAT and 5-FU compared with the standard of care in the treatment of patients with advanced, metastatic colorectal cancer.

13 Sep 2010

Enlyton publishes cancer imaging study results of colorectal cancer

Enlyton, Ltd., announced the publication of a cancer imaging study in which Enlyton's antigen-directed, cancer-specific targeting agent demonstrated superior performance over the industry standard, 18F-FDG, in Positron Emission Tomography (PET) imaging of colorectal cancer.

13 Sep 2010

UC San Diego proferssor awarded 2010 Harvey Prize in human health by Technion

Michael Karin, PhD, Distinguished Professor of Pharmacology and Pathology at the University of California, San Diego School of Medicine has been awarded the 2010 Harvey Prize in human health by the Technion, Israel's premier institute of technology.

9 Sep 2010

Aflibercept Phase 3 VELOUR clinical trial for mCRC to continue to completion

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced that the Phase 3 VELOUR clinical trial of aflibercept (VEGF Trap) in patients with metastatic colorectal cancer (mCRC) will continue to completion as planned, with no modifications due to efficacy or safety concerns. This decision is based on the recommendation of an Independent Data Monitoring Committee (IDMC) following a planned interim analysis.

9 Sep 2010

Low carbohydrate diet rich in plant-based fats and proteins associated with lower risk of mortality

Those who adhered to a diet low in carbohydrates but rich in animal-based fats and proteins increased their risk of death – especially by cancer, according to a study published in the Annals of Internal Medicine, led by Simmons College nutrition professor Teresa Fung, Sc. D.

9 Sep 2010

Preventive health services can save lives at little or no cost

Preventive health services such as daily aspirin use, tobacco cessation screening and alcohol abuse screening can potentially save 2 million lives and nearly $4 billion annually, according to a new paper produced by the National Commission on Prevention Priorities (NCPP). The NCPP is convened by the Partnership for Prevention. Four of the five lead authors perform research with HealthPartners Research Foundation.

8 Sep 2010

Jennerex, Transgene enter partnership to develop JX-594 product for tumor treatment

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene Euronext, a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that they have entered into an exclusive partnership to develop and commercialize JX-594 for the treatment of solid tumors in Europe, the Commonwealth of Independent States (CIS) and the Middle East.

8 Sep 2010

GW Cancer Institute receives grant to establish City-wide Patient Navigation Network in Washington

The GW Cancer Institute (GWCI) was recently awarded a $2.4 million grant from the D.C. Cancer Consortium to establish and coordinate a City-wide Patient Navigation Network (CPNN) in Washington, D.C.

8 Sep 2010

Rexahn Pharmaceuticals publishes research article on RX-8243 anti-tumor activity

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of a research article in Bioorganic & Medicinal Chemistry Letters on the anti-tumor activity of RX-8243 and its analogues.

3 Sep 2010

Asuragen launches KRAS, BRAF mutational testing in CLIA laboratory

Asuragen, Inc., a leader in molecular diagnostics and nucleic acid-based pharmacogenomics services, announced today that it has launched KRAS and BRAF mutational testing services in its CAP-accredited CLIA laboratory.

2 Sep 2010

Celator Pharmaceuticals raises $20 million in Series D private equity financing

Celator Pharmaceuticals, a privately held pharmaceutical company developing new and more effective therapies to treat cancer based on the company's proprietary technology, today announced that it raised $20 million in a Series D private equity financing.

2 Sep 2010

Abbott RealTime HBV assay receives marketing approval from FDA

Abbott announced today it has received approval from the U.S. Food and Drug Administration to market the Abbott RealTime HBV assay for measuring viral load or the amount of hepatitis B virus in a patient's blood. It is the first and only approved test capable of automating HBV viral load testing from sample extraction to final results.

2 Sep 2010

Eight signs of cancer: Study

Scientists have now identified eight signs of cancer that need immediate attention. These can predict the risk of cancer with such accuracy in certain age groups that patients should be referred to a specialist straight away unless there is a good explanation that is is something else.

30 Aug 2010

NICE draft guidance rejects cancer drug bevacizumab

The National Institute for Health and Clinical Excellence (NICE) has released draft guidance for cancer drug bevacizumab (Avastin).

25 Aug 2010

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Study: Capecitabine with concurrent radiation is effective for treating gastric cancer

Abbott to commercialize Celera's CE-marked KIF6 genotyping assay outside U.S.

FDA decides to review information on Avastin for advanced HER2-negative breast cancer

Researchers identify bacteria responsible for chronic intestinal inflammation

PAF announces expansion of Colorectal Care Line

Transgenomic expands EU distribution of SURVEYOR Scan K-RAS CE IVD mutation detection kit

Pro-Pharmaceuticals engages Numoda Corporation to optimize DAVANAT Phase III clinical trial

Enlyton publishes cancer imaging study results of colorectal cancer

UC San Diego proferssor awarded 2010 Harvey Prize in human health by Technion

Aflibercept Phase 3 VELOUR clinical trial for mCRC to continue to completion

Low carbohydrate diet rich in plant-based fats and proteins associated with lower risk of mortality

Preventive health services can save lives at little or no cost

Jennerex, Transgene enter partnership to develop JX-594 product for tumor treatment

GW Cancer Institute receives grant to establish City-wide Patient Navigation Network in Washington

Rexahn Pharmaceuticals publishes research article on RX-8243 anti-tumor activity

Asuragen launches KRAS, BRAF mutational testing in CLIA laboratory

Celator Pharmaceuticals raises $20 million in Series D private equity financing

Abbott RealTime HBV assay receives marketing approval from FDA

Eight signs of cancer: Study

NICE draft guidance rejects cancer drug bevacizumab

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in